@article {KOCAKOVA3455, author = {ILONA KOCAKOVA and BOHUSLAV MELICHAR and IVO KOCAK and ZBYNEK BORTLICEK and TOMAS B{\"U}CHLER and LADISLAV DUSEK and LUBO{\v S} PETRUZELKA and MILAN KOHOUTEK and JANA PRAUSOV{\'A} and JINDRICH FINEK and BEATRICE MOHELNIKOVA-DUCHONOVA and ROSTISLAV VYZULA}, title = {Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry}, volume = {35}, number = {6}, pages = {3455--3461}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To retrospectively compare the efficacy of two irinotecan-based chemotherapy regimens combined with bevacizumab in first-line therapy of metastatic colorectal cancer (mCRC). Patients and Methods: The data of 558 patients with mCRC treated with first-line bevacizumab plus irinotecan-containing regimen were obtained from the national CORECT registry that collects data of all patients with mCRC treated with targeted-agents. The treatment outcomes of patients treated with bevacizumab plus irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) were compared to patients treated with bevacizumab plus irinotecan and capecitabine (XELIRI). Results: Among 4,312 patients with CRC treated with bevacizumab, only 13\% (558) received irinotecan-based chemotherapy. No significant differences were observed in terms of progression-free survival and overall survival between FOLFIRI and XELIRI groups. Moreover, the toxicity of both regimens was also comparable. Conclusion: This retrospective analysis confirms the comparable activity of FOLFIRI and XELIRI regimens when combined with bevacizumab.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/6/3455}, eprint = {https://ar.iiarjournals.org/content/35/6/3455.full.pdf}, journal = {Anticancer Research} }